Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety, Pharmacokinetics, and Efficacy of Topical 3% Amphotericin B Cream for the Treatment of Uncomplicated Cutaneous Leishmaniasis in Colombia
Brief Summary: The proposed study encompasses a two-step approach. The first aiming to determine the safety of Topical 3% Amphotericin B Cream when applied three or two times per day for 4 weeks in subjects with un-complicated Cutaneous leishmaniasis (CL) whilst the second focusing in having and indication of the efficacy of the two above mentioned regimens of Topical 3% Amphotericin B Cream

For the first step, 30 subjects will be randomly assigned to receive direct observed treatment (DOT) with Topical 3% Amphotericin B Cream applied either three or two times per day for 4 weeks. Enrolment will be temporarily halted until all 30 subjects (15 in each group) have been enrolled and completed the 28 day treatment course. An interim analysis of all safety (Adverse Events, including local reactions and lab parameters) and pharmacokinetics collected on subjects who were randomized will be performed by data safety monitoring board. If no serious adverse events (SAEs) related to the study drug are identified on the first 30 subjects by the end of the treatment course, 50 additional subjects will be randomly allocated to receive Topical 3% Amphotericin B Cream either three or two times per day for 28 days

Subjects will have a follow-up visit at the end of therapy, on Day 45± 5 days, Day 63± 5 days and on Days 90± 14 days and on Day 180, minus 14d, plus 4 weeks to assess efficacy, as measured by the number of subjects who fulfil the cure criteria: 100% re-epithelialization of the lesion(s) by Day 90 and no relapse by Day 180. All subjects will be followed up to Day 180 for final analysis of efficacy.


Options:
A: Arm Label: Topical Amphotericin B three times per day; Type: EXPERIMENTAL; Interventions: Drug: Topical Amphotericin B at 3% | Arm Label: Topical Amphotericin B two times per day; Type: EXPERIMENTAL; Interventions: Drug: Topical Amphotericin B at 3% | Intervention Type: DRUG; Name: Topical Amphotericin B at 3%; Assigned to Arm(s): Topical Amphotericin B three times per day, Topical Amphotericin B two times per day
B: Arm Label: Paromomycin Alone Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paromomycin Alone Cream (15% paromomycin topical cream) | Arm Label: WR 279,396; Type: ACTIVE_COMPARATOR; Interventions: Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) | Intervention Type: DRUG; Name: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Paromomycin Alone Cream (15% paromomycin topical cream); Assigned to Arm(s): Paromomycin Alone Treatment
C: Arm Label: High dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meglumine antimoniate | Arm Label: Low dose; Type: EXPERIMENTAL; Interventions: Drug: Meglumine antimoniate | Intervention Type: DRUG; Name: Meglumine antimoniate; Assigned to Arm(s): High dose, Low dose
D: Intervention Type: BIOLOGICAL; Name: Leish-111f + MPL-SE vaccine; Assigned to Arm(s): N/A

Answer: A